tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Mehta RS et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. 2016 Br. J. Haematol. pmid:26947769
Kiyohara H et al. Up-to-date medical treatment for ulcerative colitis. 2016 Nihon Shokakibyo Gakkai Zasshi pmid:26947041
Carcas-Sansuán AJ Limited sampling strategies for once daily tacrolimus exposure monitoring. 2016 Eur. J. Clin. Pharmacol. pmid:26939899
Iguchi A et al. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation. 2016 Pediatr Transplant pmid:26526424
Fukuta T et al. Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity. 2016 Sci Rep pmid:27440054
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Kolb M et al. Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation. 2016 Biol. Blood Marrow Transplant. pmid:26880117
Arreola-Guerra JM et al. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. 2016 Ann. Transplant. pmid:26879833
Žilinská Z et al. Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation. 2016 Transplant. Proc. pmid:27788794
Dharnidharka VR et al. Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. 2016 Transpl. Int. pmid:27564782
Rostaing L et al. Successful Transplantation in ABO- and HLA-Incompatible Living Kidney Transplant Patients: A Report on 12 Cases. 2016 Ther Apher Dial pmid:27073167
Pirojsakul K et al. Management of sensitized pediatric patients prior to renal transplantation. 2016 Pediatr. Nephrol. pmid:26801944
Guo YW et al. Successful treatment of ileal ulcers caused by immunosuppressants in two organ transplant recipients. 2016 World J. Gastroenterol. pmid:27350740
Nekkanti V et al. Design, Characterization, and In Vivo Pharmacokinetics of Tacrolimus Proliposomes. 2016 AAPS PharmSciTech pmid:26729532
Armand P et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. 2016 Br. J. Haematol. pmid:26729448
Badr R et al. Assessment of global ischemic/reperfusion and Tacrolimus administration on CA1 region of hippocampus: gene expression profiles of BAX and BCL2 genes. 2016 Bratisl Lek Listy pmid:27546370
Hanaoka K et al. A chronic renal rejection model with a fully MHC-mismatched rat strain combination under immunosuppressive therapy. 2016 Transpl. Immunol. pmid:27545900
Matsa E et al. Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. 2016 Cell Stem Cell pmid:27545504
Thao le Q et al. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues. 2016 Int J Pharm pmid:26657273
Mokuda S and Oiwa H Successful treatment of FKBP51-expressed multicentric reticulohistiocytosis using combination therapy with low-dose denosumab and tacrolimus. 2016 Scand. J. Rheumatol. pmid:26652057
Albeiroti S et al. Evaluation of 2 Batched Pretreatment Systems for the Measurement of Whole Blood Tacrolimus on the ARCHITECT Immunoassay Analyzer. 2016 Lab Med pmid:27474776
Yu H et al. Risk factors for new-onset diabetes mellitus after living donor kidney transplantation in Korea - a retrospective single center study. 2016 BMC Nephrol pmid:27473469
Filler G et al. Minimum mycophenolic acid levels are associated with donor-specific antibody formation. 2016 Pediatr Transplant pmid:26589470
Scalea JR et al. Tacrolimus for the prevention and treatment of rejection of solid organ transplants. 2016 Expert Rev Clin Immunol pmid:26588770
Sakai R et al. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. 2016 Int. J. Hematol. pmid:26800676
Pouché L et al. New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. 2016 Pharmacogenomics pmid:26799749
Wu SY et al. Comprehensive risk assessment for early neurologic complications after liver transplantation. 2016 World J. Gastroenterol. pmid:27350733
Constantinescu AA et al. Differential influence of tacrolimus and sirolimus on mitochondrial-dependent signaling for apoptosis in pancreatic cells. 2016 Mol. Cell. Biochem. pmid:27344165
Shao K et al. Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation. 2016 Scand. J. Immunol. pmid:26524694
Cena T et al. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients. 2016 Transpl. Int. pmid:27343849
Binkhathlan Z et al. Reutilization of Tacrolimus Extracted from Expired Prograf® Capsules: Physical, Chemical, and Pharmacological Assessment. 2016 AAPS PharmSciTech pmid:26729529
Pizzo HP et al. Sirolimus and tacrolimus coefficient of variation is associated with rejection, donor-specific antibodies, and nonadherence. 2016 Pediatr. Nephrol. pmid:27286686
Fernández de Castillo Torras L et al. Treatment with ulipristal acetate (Esmya(®)) and plasma levels of tacrolimus: a case report. 2016 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:27282803
Youssef M et al. Asymptomatic papulonodular lesions in zosteriform distribution in an immunocompromised patient. 2016 Int. J. Dermatol. pmid:26463835
Ferjani H et al. The evaluate and compare the effects of the Tacrolimus and Sirolimus on the intestinal system using an intestinal cell culture model. 2016 Toxicol. Mech. Methods pmid:26460985
Sasaki T et al. Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients. 2016 Clin. Rheumatol. pmid:25644583
Nerattini F et al. II. Dissociation free energies in drug-receptor systems via nonequilibrium alchemical simulations: application to the FK506-related immunophilin ligands. 2016 Phys Chem Chem Phys pmid:27193181
O'Regan JA et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. 2016 J. Nephrol. pmid:26374111
Seok J et al. Recalcitrant steroid-induced rosacea successfully treated with 0.03% tacrolimus and 595-nm pulsed dye laser. 2016 Eur J Dermatol pmid:27193042
Caillard S et al. Advagraf(®) , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. 2016 Transpl. Int. pmid:26373896
Reiner J et al. After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum. 2016 Transplant. Proc. pmid:27109987
Rao B et al. Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 2016 Transplant. Proc. pmid:27109983
Chang HK et al. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital. 2016 Transplant. Proc. pmid:27109981
Kishida N et al. Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. 2016 Ann. Transplant. pmid:27956735
Wang Y et al. Preparation, characterization and in vivo evaluation of amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization method. 2016 Int J Pharm pmid:27034003
Jimbo H et al. Telangiectatic lichen sclerosus on the cheek successfully treated with topical tacrolimus. 2016 Eur J Dermatol pmid:27033557
Shimizu K et al. Specific delivery of an immunosuppressive drug to splenic B cells by antigen-modified liposomes and its antiallergic effect. 2016 J Drug Target pmid:27030163
Yan Y et al. Robust Axonal Regeneration in a Mouse Vascularized Composite Allotransplant Model Undergoing Delayed Tissue Rejection. 2016 Hand (N Y) pmid:28149214
Carrillo-Ibarra S et al. The Oxidative and Inflammatory State in Patients with Acute Renal Graft Dysfunction Treated with Tacrolimus. 2016 Oxid Med Cell Longev pmid:27872679
Thomusch O et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. 2016 Lancet pmid:27871759